publication . Article . 2014

The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology:A Systematic Review and Exploratory Meta-analysis

John Mair-Jenkins; Maria Saavedra-Campos; J. Kenneth Baillie; Paul Cleary; Fu-Meng Khaw; Wei Shen Lim; Sophia Makki; Kevin Rooney; Jonathan S. Nguyen-Van-Tam; Charles R. Beck; ...
Open Access English
  • Published: 16 Jul 2014
  • Country: United Kingdom
<p>BACKGROUND: Administration of convalescent plasma, serum, or hyperimmune immunoglobulin may be of clinical benefit for treatment of severe acute respiratory infections (SARIs) of viral etiology. We conducted a systematic review and exploratory meta-analysis to assess the overall evidence.</p><p>METHODS: Healthcare databases and sources of grey literature were searched in July 2013. All records were screened against the protocol eligibility criteria, using a 3-stage process. Data extraction and risk of bias assessments were undertaken.</p><p>RESULTS: We identified 32 studies of SARS coronavirus infection and severe influenza. Narrative analyses revealed consis...
free text keywords: Major Articles and Brief Reports, Viruses, MERS coronavirus, convalescent plasma, severe acute respiratory infection, systematic review, meta-analysis, Infectious Diseases, Immunology and Allergy, Confidence interval, Placebo, Intensive care medicine, medicine.medical_specialty, medicine, Clinical trial, business.industry, business, Respiratory tract infections, Middle East respiratory syndrome coronavirus, medicine.disease_cause, Internal medicine, Meta-analysis, Odds ratio, Prospective cohort study
50 references, page 1 of 4

Middle East respiratory syndrome coronavirus (MERS-CoV)—update (26 May 2014).

Clinical management of severe acute respiratory infections when novel coronavirus is suspected: what to do and what not to do.

Treatment of MERS-CoV: decision support tool v.1.0.

State of knowledge and data gaps of middle east respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr Outbreaks. 2013

Hung, IFN, To, KKW, Lee, C-K. Hyperimmune iv immunoglobulin treatment: A multicenter double-blind randomized controlled trial for patients with severe 2009 influenza a(H1N1) infection. Chest. 2013; 144: 464-73 [PubMed]

Lai, ST. Treatment of severe acute respiratory syndrome. Eur J Clin Microbiol Infect Dis. 2005; 24: 583-91 [OpenAIRE] [PubMed]

Stockman, LJ, Bellamy, R, Garner, P. SARS: systematic review of treatment effects. PLoS Med. 2006; 3: e343 [OpenAIRE] [PubMed]

Yeh, KM, Chiueh, TS, Siu, LK. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005; 56: 919-22 [OpenAIRE] [PubMed]

Wong, SS, Yuen, KY. The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother. 2008; 62: 437-41 [OpenAIRE] [PubMed]

Moher, D, Liberati, A, Tetzlaff, J, Altman, DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6: e1000097 [OpenAIRE] [PubMed]

Mair-Jenkins, J, Saavedra-Campos, M, Nguyen-Van-Tam, J, Beck, C. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the effectiveness of convalescent plasma for the treatment of severe acute respiratory infections of viral aetiology: a systematic review. PROSPERO 2013CRD42013005091.

Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Updated March 2011. 2011

Tugwell, P, Wells, G. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses.

West, S, King, V, Carey, T, Lohr, K, McKoy, N, Sutton, S. Systems to rate the strength of scientific evidence: summary. 2002

Systematic Reviews: CRD's guidance for undertaking reviews in health care. 2009

50 references, page 1 of 4
Any information missing or wrong?Report an Issue